ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1050 • ACR Convergence 2023

    Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols

    Fabian Carranza Enriquez1, Carina Soto-Fajardo1, Sinthia Solorzano Flores1, Abish Angeles-Acuña1, Mayra Mejia-Avila2, Amyrari Vázquez-Ortega3, Paola Flores-Ordoñez2, Karina Arias Callejas2, Alejandra Enriquez-Luna4, Graciliano Ramon-Diaz4, Brenda Bravo-Zarate2, Tatiana Sofía Rodríguez-Reyna3 and Carlos Pineda4, 1Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 2Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Instituto Nacional de Rehabilitacion, Mexico City, Mexico

    Background/Purpose: Lung ultrasound (LUS) has proven useful to detect interstitial lung disease (ILD) among patients with SSc when compared to high-resolution computerized tomography (HRCT) as…
  • Abstract Number: 1040 • ACR Convergence 2023

    Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT

    Juan Molina-Collada1, Isabel Castrejon2, Irene Monjo3, Elisa Fernandez-Fernandez4, Gabriela Torres5, JULIA MARTINEZ BARRIO6, Jose María Alvaro-Gracias7 and Eugenio De Miguel5, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3University Hospital La Paz, Madrid, Spain, 4La Paz University Hospital, Madrid, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 7Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Aortitis is a serious potential complication of patients with giant cell arteritis (GCA) and may lead to dilation, aneurysms or dissection. Since ultrasound (US)…
  • Abstract Number: 1027 • ACR Convergence 2023

    Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis

    Bella Mehta1, Kaylee Ho2, J. Alex Gibbons3, Vicki Ling4, Susan Goodman5, Michael Parks5, Bheeshma Ravi6, Fei Wang2, Said Ibrahim7 and Peter cram8, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Columbia University Vagelos College of Physicians & Surgeons, New York, NY, 4Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 5Hospital for Special Surgery, New York, NY, 6Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 7Northwell Health, New York, NY, 8The University of Texas Medical Branch, Galveston, TX

    Background/Purpose: Access to care varies across health systems. Countries with universal health insurance are thought to have less wealth-based health disparities, but it is unclear…
  • Abstract Number: 0987 • ACR Convergence 2023

    Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)

    Vijaya Rivera Terán1, David Vega Morales2, Miguel Angel Saavedra Salinas3, Iris Colunga4, Sandra Carrillo Vazquez5, Dafhne Miranda Hernández6, Sergio Durán Barragán7, Erick Adrián Zamora Tehozol8, Daniel Xavier Xibillé Friedman9, Angel Alejandro Castillo Ortiz10, Sandra Sicsik Ayala11, Fedra Irazoque Palazuelos5, Julio César Casasola Vargas12, Angelica Peña13, Omar Eloy Muñoz Monroy14, Azucena Ramos Sánchez2, Luis Valdés Corona15, Javier Merayo-Chalico16, Estefania Torres Valdez13, Aleni Paz Viscarra15, Samara Mendieta Zerón17 and Deshiré Alpízar Rodríguez1, 1Colegio Mexicano de Reumatología, Mexico City, Mexico, 2Instituto Mexicano del Seguro Social, Monterrey, Mexico, 3IMSS, Mexico City, Mexico, 4Hospital Universitario UANL, Monterrey, Mexico, 5Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, 6Instituto Mexicano del Seguro Social, Mexico City, Mexico, 7Consulta Privada, Guadalajara, Mexico, 8Centro Médico Pensiones, Mérida, Mexico, 9Práctica Privada, Cuernavaca, Mexico, 10Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, 11Instituto Mexicano del Seguro Social, Torreón, Mexico, 12Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, 13Instituto Mexicano del Seguro Social, Querétaro, Mexico, 14Hospital Central Militar, Mexico City, Mexico, 15Práctica Privada, Mexico City, Mexico, 16Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico, 17Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico

    Background/Purpose: Genetic, demographic, clinical, and immunological factors have been related with the response to treatment in inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) and…
  • Abstract Number: 0999 • ACR Convergence 2023

    Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization

    Kranti Rumalla1, Sumanth Chandrupatla2 and Jasvinder Singh2, 1Northwestern School of Medicine, Chicago, IL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Over 450,000 primary total hip arthroplasties (THA) are performed each year. One major indication for primary THA is the presence of osteoarthritis (OA). Patient…
  • Abstract Number: 0853 • ACR Convergence 2023

    Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System

    Shruthi Srivatsan1, Zachary Williams1, Claire Cook1, Xiaoqing Fu1, Naomi Patel1 and Zachary Wallace2, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Newton, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…
  • Abstract Number: 1063 • ACR Convergence 2023

    Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

    Jenny Li1, Marie Hudson2, Carrie Ye3, Janet Roberts4, Aurore Fifi-Mah5, May Choi5, Sabrina Hoa6, Thomas Appleton7, Janet Pope7, Nancy Maltez8, Lourdes Gonzalez Arreola9, Anthony Obrzut9 and Shahin Jamal10, 1University of British Columbia, Vancouver, BC, Canada, 2McGill University, Montréal, QC, Canada, 3University of Alberta, Edmonton, AB, Canada, 4Dalhousie University, Halifax, NS, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Montreal, Brossard, QC, Canada, 7University of Western Ontario, London, ON, Canada, 8The Ottawa Hospital, Ottawa, ON, Canada, 9Arthritis Research Canada, Vancouver, BC, Canada, 10Vancouver Coastal Health, Vancouver, BC, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…
  • Abstract Number: 1011 • ACR Convergence 2023

    A Rheumatology Model of Care Re-design: Integrating the Advanced Practice Provider

    Lisa Carnago1, Kristin Holbrook2, David Leverenz3, Natalie Rivera4 and Allison Dimsdale5, 1Duke Health, Hillsborough, NC, 2Duke Health, Raleigh, NC, 3Duke University School of Medicine, Durham, NC, 4Children's National Hospital, Washington, DC, 5PDC Advanced Practice, Duke School of Nursing, Durham, NC

    Background/Purpose: There is a lack of guidance surrounding integration of Advanced Practice Providers (APPs) into specialty practices utilizing interprofessional Models of Care (MoC). Due to…
  • Abstract Number: 1071 • ACR Convergence 2023

    No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

    Madeline O'Sullivan1, Grant Cannon1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel4, Jessica A Walsh5, Punyasha Roul6, Bryant England6, Ted R Mikuls7, Joshua Baker8 and Tawnie Braaten4, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4University of Utah, Salt Lake City, UT, 5Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 6University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
  • Abstract Number: 1080 • ACR Convergence 2023

    Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study

    Antoine Minier1, Gilles Boire1, Sophie ROUX1, Nathalie Carrier2 and Hugues Allard-Chamard1, 1Université de Sherbrooke, Sherbrooke, QC, Canada, 2CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada

    Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE)…
  • Abstract Number: 1079 • ACR Convergence 2023

    Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements

    Tawnie Braaten1, Selene Rubino1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel1, Jessica A Walsh4, Shardool Patel5 and Grant Cannon5, 1University of Utah, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
  • Abstract Number: 1067 • ACR Convergence 2023

    A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis

    Carlos Aude1, Deanna Jannat-Khah2, Karmela Kim Chan2, Nilasha Ghosh1, Clifton Bingham3, Vivian Bykerk2 and Anne Bass1, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Hospital For Special Surgery, New York, NY, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but may trigger immune-related adverse events (irAEs) such as ICI-induced inflammatory arthritis (ICI-IA). Although ICI-IA and…
  • Abstract Number: 1081 • ACR Convergence 2023

    Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial

    Marthe Brun1, Kristin Hammersbøen Bjørlykke2, Johanna E. Gehin3, David John Warren3, Rolf A. Klaasen3, Joseph Sexton1, Øystein Sandanger4, Tore Kvien1, Cato Mørk5, Jørgen Jahnsen2, Nils Bolstad3, Kristin Kaasen Jørgensen2, Espen Haavardsholm1, Guro Goll1 and Silje Watterdal Syversen1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 3Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 4Section of Dermatology, Oslo University Hospital, Oslo, Norway, 5Akershus Dermatology Center, Lørenskog, Norway

    Background/Purpose: Formation of anti-drug antibodies (ADAb) to biological drugs is a clinical problem. Proactive therapeutic drug monitoring (TDM) allows for timely detection of ADAb and…
  • Abstract Number: 1083 • ACR Convergence 2023

    A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative

    Rachel Dayno1, Sarah Capponi2, Stephanie Song3, Sarah Bayefsky4, Thomas Riley5, Marta Bean1, John Oghene3, Jonathan Kotzin1, Ellen Romich6, Paula Breslin-Perry1, Nora Sandorfi1, Preethi Thomas7 and Michael George1, 1University of Pennsylvania, Philadelphia, PA, 2Hospital of the University of Pennsylvania, New Hope, PA, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 5Hopsital of the University of Pennsylvania, Springfield, PA, 6Hospital of the University of Pennsylvania, Media, PA, 7University of Pennsylvania, Conshohocken, PA

    Background/Purpose: People with systemic rheumatologic diseases are more susceptible to herpes zoster (HZ) infection and its complications due to their underlying diseases and the medications…
  • Abstract Number: 1087 • ACR Convergence 2023

    Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach

    Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA

    Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
  • « Previous Page
  • 1
  • …
  • 314
  • 315
  • 316
  • 317
  • 318
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology